Rapid Micro Biosystems, Inc. (RPID) Stock Price & Analysis
Rapid Micro Biosystems, Inc. (RPID) rose 0.00% to USD 1.99 as of July 25, 2026 at 03:43 UTC, according to Nexqual real-time market data.
RPID last closed at USD 1.99; the session ranged USD 1.95–2.02 on volume of 193,519 shares. Market capitalization is $99.15M, with a 52-week range of USD 1.66–4.94 (NCM). Source: Nexqual, July 25, 2026 at 03:43 UTC.
Key Statistics (as of July 25, 2026 at 03:43 UTC)
| Price | USD 1.99 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.99 |
| Open | USD 2 |
| Day Range | USD 1.95 – 2.02 |
| 52-Week Range | USD 1.66 – 4.94 |
| Volume | 193,519 shares |
| Market Cap | $99.15M |
| Exchange | NCM |
Technical Analysis (RPID)
Nexqual's technical model rates RPID "BUY" based on 4 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 03:43 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 51.34 (neutral) |
| vs SMA50 | Above (USD 1.92) |
| MACD | 0.05 (positive) |
Analyst Ratings (RPID)
Wall Street analysts rate RPID "None" based on 3 analysts, with a mean price target of USD 6.67 (range USD 5–8), per Nexqual as of July 25, 2026 at 03:43 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 6.67 |
| High Target | USD 8 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (RPID)
| Next Earnings Date | 2026-08-07 |
|---|---|
| EPS Estimate | USD -0.24 |
| Revenue Estimate | $7.88M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.31 vs est -0.25 ▼ miss |
| 2025-12-31 | USD -0.28 vs est -0.23 ▼ miss |
| 2025-09-30 | USD -0.26 vs est -0.25 ▼ miss |
| 2025-06-30 | USD -0.27 vs est -0.25 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:43 UTC.
Financials & Fundamentals (RPID)
| Total Revenue | $34.38M |
|---|---|
| Revenue Growth (YoY) | +11.10% |
| Gross Margin | +2.95% |
| Operating Margin | -173.11% |
| Profit Margin | -145.81% |
| ROE | -116.74% |
| Debt / Equity | 116.24 |
| Current Ratio | 2.58 |
| Total Cash | $23.72M |
| Total Debt | $23.71M |
| Free Cash Flow | $-19.89M |
Source: Nexqual, July 25, 2026 at 03:43 UTC.
Financial Health Score (RPID)
Nexqual rates Rapid Micro Biosystems, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:43 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $24M cash vs $24M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$20M, burning cash |
| Efficiency | Critical — ROE -117%, ROA -41.9% |
Ownership (RPID)
| Insider Ownership | +10.26% |
|---|---|
| Institutional Ownership | +43.15% |
| Shares Outstanding | 45.32M |
| Float | 30.11M |
| Short % of Float | +2.41% |
Source: Nexqual, July 25, 2026 at 03:43 UTC.
Leadership (RPID)
Rapid Micro Biosystems, Inc. is led by Robert G. Spignesi (age 55), CEO, President, COO & Director, per Nexqual as of July 25, 2026 at 03:43 UTC.
| CEO, President, COO & Director | Robert G. Spignesi (age 55) |
|---|---|
| Chief Financial Officer | Sean M. Wirtjes (age 56) |
| Vice President of Investor Relations & Corporate Communications | Michael Beaulieu C.F.A. |
Major Backers & Investors (RPID)
Notable institutional backers of Rapid Micro Biosystems, Inc. include Bain Capital Life Sciences Investors, LLC, ABG-WTT Global Life Science Capital Partners GP Ltd, Essex Investment Management Co LLC, according to Nexqual as of July 25, 2026 at 03:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bain Capital Life Sciences Investors, LLC | 20.24% |
| ABG-WTT Global Life Science Capital Partners GP Ltd | 4.44% |
| Essex Investment Management Co LLC | 2.12% |
| Advent International LP | 1.33% |
| Evernest Financial Advisors, LLC | 1.04% |
| SEI Investments Co | 0.68% |
| Millennium Management | 0.68% |
| Legato Capital Management LLC | 0.66% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.65% |
| Geode Capital | 0.59% |
Source: Nexqual, July 25, 2026 at 03:43 UTC.
From Rapid Micro Biosystems, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Through our unique expertise at the intersection of microbiology, robotic systems, and advanced vision algorithms, we are setting the foundation for end-to-end quality control automation to enable the future of advanced pharmaceutical manufacturing.
- Our proprietary technology works by replacing human counting of growing colonies with software and algorithm detection and counting based on image analysis.
- Drive new customer adoption of the Growth Direct platform by converting the leading manufacturers in our core markets, including top 50 pharmaceutical companies and leading CDMOs — There are 49 global customers that have adopted the Growth Direct platform to automate MQC testing in 107 manufacturing facilities.
- Our platform comprises the Growth Direct system, proprietary consumables, lab information management system ("LIMS") connection and other software, and comprehensive customer support and validation services.
Partnerships
- We originally developed our platform in close collaboration with our customers, and our customers' success in validating our technology constitutes a major driver for platform deployment.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SGHT | Sight Sciences, Inc. | USD 4.91 | ▼ 2.39% |
| CTKB | Cytek Biosciences, Inc. | USD 4.46 | ▼ 1.76% |
| AIRS | AirSculpt Technologies, Inc. | USD 4.61 | ▼ 4.36% |
| TMCI | Treace Medical Concepts, Inc. | USD 4 | ▲ 0.76% |
| DSGN | Design Therapeutics, Inc. | USD 11.78 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:43 UTC. This page is informational and not investment advice.